Coeptis therapeutics holdings, inc.COEPW.US Overview
COEPW Overall Performance
COEPW AI Analysis & Strategy
COEPW Recent Performance
-
Coeptis therapeutics holdings, inc.
0.29%
Avg of Sector
0.14%
S&P500
COEPW PowerScanner
COEPW Key Information
COEPW Valuation Metrics
COEPW Earnings Table
COEPW Profile
Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops and commercializes generic and branded pharmaceutical products and cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a Vy-Gen drug product for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; and CD38-Diagnostic, an in vitro screening tool to provide the ability to pre-determine which cancer patients are most likely to benefit from targeted anti-CD38 monoclonal antibodies therapies. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics Holdings, Inc. was founded in 2017 and is headquartered in Wexford, Pennsylvania.